News and views
February 2015 Br J Cardiol 2015;22:18 Online First
News from the British Society for Heart Failure 17th Annual Autumn Meeting
'Yesterday’s problems, today’s solutions' was the theme of the 2014 autumn meeting of the British Society for Heart Failure (BSH). A wide-ranging programme covered many topics from uncertainties, myths and dogmas to frightening calls and consultations including the heart failure patient with cancer. Drs Lindsey Tilling and Eleanor Wicks report some of its highlights....
February 2015 Br J Cardiol 2015;22:11 Online First
Correspondence: accurate classification of chest pain
Correspondence from the world of cardiology...
February 2015 Br J Cardiol 2015;22:11 Online First
Correspondence: don’t see their heart broken
Correspondence from the world of cardiology...
February 2015 Br J Cardiol 2015;22:11 Online First
Correspondence: mortality due to rheumatic heart disease
Correspondence from the world of cardiology...
February 2015 Br J Cardiol 2015;22:25 Online First
Book review
The antibody molecule: from antitoxins to therapeutic antibodies...
January 2015 Br J Cardiol 2015;22:12–13 Online First
News from the American Heart Association Scientific Sessions 2014
The latest mega trial − IMPROVE-IT − dominated discussion at the recent American Heart Association (AHA) Scientific Sessions, with ezetimibe becoming the first non-statin lipid lowering agent to reduce clinical events. Other major talking points at the meeting, held in Chicago on 15th−19th November 2014, were the optimal duration for dual antiplatelet therapy after drug-eluting stent placement, whether oxygen may be harmful for STEMI patients who are not hypoxic, and more doubts about aspirin in primary prevention. ...
January 2015 Br J Cardiol 2015;22:(1) Online First
Lipid highlights from the American Heart Association
Non-statin lipid lowering was the focus of several studies reporting at the recent American Heart Association (AHA) Scientific Sessions in Chicago, USA. It was dominated by results from IMPROVE-IT, the first outcome study to show clinical events being reduced by a non-statin lipid lowering agent. Results from the ODYSSEY studies with PCSK9 inhibitors also reporting at the meeting continue to look promising with dramatic reductions in cholesterol seen. There was also good news for the long-term use of statins reported at the meeting. 20-year follow-up in the WOSCOPS study show a lifetime benefit after five years statin therapy and confirmation of their safety. With clinicians increasingly asking how low can we go with cholesterol lowering, this report puts these studies in perspective for UK practice as well as summarising key results. Some of the physicians we interviewed here also talk about the implications of the studies in our AHA podcast....
January 2015 Online First
American Heart Association Scientific Sessions 2014
Highlights of studies presented at the 2014 American Heart Association Scientific Sessions, put into a UK perspective. Professor Tony Wierzbicki talks about the relevance of the IMPROVE-IT study for UK practice, and Professor Robin Choudhury examines the diagnosis of statin intolerance....
